S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:ATRS

Antares Pharma Stock Forecast, Price & News

$4.28
-0.06 (-1.38 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.27
Now: $4.28▼
$4.42
50-Day Range
$3.03
MA: $3.69▼
$4.29
52-Week Range
$1.60
Now: $4.28▼
$4.58
Volume1.04 million shs
Average Volume1.45 million shs
Market Capitalization$713.36 million
P/E Ratio71.35
Dividend YieldN/A
Beta1.44
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Antares Pharma logo

MarketRank™

Overall MarketRank™

1.80 out of 5 stars

Medical Sector

103rd out of 1,480 stocks

Surgical & Medical Instruments Industry

17th out of 135 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
Previous Symbol
CUSIP03664210
CIK1016169
Webwww.antarespharma.com
Phone609-359-3020
Employees178

Debt

Debt-to-Equity Ratio0.53
Current Ratio2.47
Quick Ratio2.08

Price-To-Earnings

Trailing P/E Ratio71.35
Forward P/E Ratio71.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$123.86 million
Price / Sales5.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.33 per share
Price / Book12.97

Profitability

EPS (Most Recent Fiscal Year)($0.01)
Net Income$-2,030,000.00
Net Margins6.64%
Return on Equity16.48%
Return on Assets6.69%

Miscellaneous

Outstanding Shares166,672,000
Market Cap$713.36 million
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$4.28
-0.06 (-1.38 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

How has Antares Pharma's stock been impacted by Coronavirus?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATRS shares have increased by 42.7% and is now trading at $4.28.
View which stocks have been most impacted by COVID-19.

Is Antares Pharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Antares Pharma stock.
View analyst ratings for Antares Pharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Antares Pharma?

Wall Street analysts have given Antares Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antares Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Antares Pharma.

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) posted its earnings results on Tuesday, November, 10th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.01. The specialty pharmaceutical company earned $40 million during the quarter, compared to the consensus estimate of $36.09 million. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%.
View Antares Pharma's earnings history.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2021 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $175-200 million, compared to the consensus revenue estimate of $187.24 million.

What price target have analysts set for ATRS?

4 brokerages have issued 12 month price objectives for Antares Pharma's shares. Their forecasts range from $4.50 to $7.00. On average, they anticipate Antares Pharma's stock price to reach $5.63 in the next year. This suggests a possible upside of 31.4% from the stock's current price.
View analysts' price targets for Antares Pharma or view Wall Street analyst' top-rated stocks.

Who are some of Antares Pharma's key competitors?

Some companies that are related to Antares Pharma include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR) and Anika Therapeutics (ANIK).
View all of ATRS's competitors.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 55, Pay $1.01M)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 60, Pay $590.73k)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 54, Pay $613.48k)
  • Mr. Patrick Madsen, Sr. VP of Operations
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 58)
  • Ms. Tram Bui, VP of Corp. Communications & Investor Relations
  • Mr. Edward Tykot, Sr. VP of Corp. Bus. Devel.
  • Dr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 73)
  • Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer
  • Mr. Greg Defilippis, Sr. VP of Device Bus. & Alliances

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.02%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for Antares Pharma or view top insider-selling stocks.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $4.28.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $713.36 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 178 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.